HUM vs MYGN: fair value comparison
Humana Inc. and Myriad Genetics, Inc. · Updated 2026-10-19
MYGN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, HUM currently ranks higher by quality score.
| HUM | MYGN | |
|---|---|---|
| Verdict | Overvalued | No estimate yet |
| Last price | $431.87 | $3.98 |
| 12-month range | $163.67–$433.50 | $2.86–$8.18 |
| Rank by discount to fair value | #90 of 108 Healthcare | — |
| Rank by quality score | #199 of 301 Healthcare | #201 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | Strong | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: HUM fair value analysis · MYGN fair value analysis